Business
LYT-300 Achieves Proof-of-Principle in Human Study
LYT-300 Achieves Proof-of-Principle in Human Study.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n 14 June 2022\n \n \n \n \n \n \n \n \n \n PureTech\n \n \n Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300\n \n \n \n \n \n \n \n \n \n LYT-300 achieved systemic blood levels approximately nine-fold greater compared to previous reports with oral allopregnanolone.1 Allopregnanolone is a neurosteroid with proven efficacy that is currently only approved as a 60-hour intravenous infusion.\n \n \n \n \n \n \n \n \n \n LYT-300, an orally administered prodrug of allopregnanolone, is designed to be differentiated from synthetic analogs, which may not replicate the full target engagement profile of natural allopregnanolone.\n \n \n \n \n \n \n \n \n \n These clinical data establish proof-of-principle for PureTech's Glyph™platform for enabling oral administration of a range of therapeutics.\n \n \n \n \n \n \n \n PureTech Health plc\n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the achievement of\n proof-of-principle for its Glyph™ platform in a healthy adult study of LYT-300 (oral allopregnanolone), PureTech's wholly-owned therapeutic candidate for the potential treatment of a range of neurological and neuropsychological conditions. This is a key milestone for the candidate, which is designed to overcome the normally poor oral bioavailability of allopregnanolone to deliver its proven efficacy via simple, convenient oral dosing. This is also the first mechanistic proof-of-principle in the clinic for PureTech's Glyph lymphatic targeting platform, which is designed to\n bypass first-pass metabolism to help maximize the therapeutic potential of validated targets and drugs where oral bioavailability has been a barrier. The Glyph platform is also designed to have additional applications through its ability to selectively traffic therapeutics into the lymphatic system, potentially enabling more direct targeting of the immune system.\n \n \n \n \n \n \"Natural allopregnanolone has demonstrated efficacy for the treatment of postpartum depression\n (PPD) and other neuropsychological conditions, but up to now has required IV deli...